Amphista Therapeutics is a UK-based  company creating first-class therapeutics to selectively degrade and remove disease-causing proteins by harnessing the body’s natural processes.

It’s next generation targeted protein degradation TPD-based medicines leverage novel mechanisms that make use of a wider range of the body’s own innate protein degrading capabilities. Amphista’s proprietary drug development approach gives patients the potential to overcome many of the limitations seen with current therapeutic approaches, providing the opportunity to treat a wider range of diseases. Its innovative technology could benefit several hundreds of thousands of patients with improved treatment, particularly in oncology and neurodegenerative diseases.

Amphista raised a $53m (£38m) Series B financing co-led by Gilde Healthcare to further develop its differentiated TPD platform and bring drug candidates to the clinic.